The brave first person to trial a coronavirus vaccine has spoken out on Good Morning Britain as the fight against Covid-19 continues.

As the first trials on humans are launched in the UK, the first patient to trial appeared on GMB on Thursday morning.

He was interviewed by Susanna Reid as part of Thursday's instalment of the ITV1 daytime favourite.  Watch the chilling interview above.

And after taking part, he was quizzed by Susanna and her co-presenter Piers Morgan, where he listed some worrying side effects.

Simeon Courtie, who has not actually had the coronavirus, explained on Good Morning Britain why he is volunteering for the vaccine trials and what the scary side effects are.

The novelist revealed the side effects to the vaccine include flu-like symptoms, and at worst a fever for several days and aches and pains.

But the brave guest added: "It shouldn't be too disruptive."

He explained: "We are the safety part of this process to see if it's safe, and after my trial there will be an efficacy trial in the community to see if it works on thousands of people."

Piers Morgan thanked Simeon for his bravery and stepping forward to help out in the time of crisis.

Simon also tweeted: "Very happy to be invited onto  @GMB  with  @susannareid100  and  @piersmorgan  today to talk about volunteering on the Oxford Vaccine Trial which starts today. Good luck to the amazing scientists at  @JennerInstitute  ".

The government has launched the trial, with Health Secretary Matt Hancock saying he is "throwing everything at" fighting Covid-19.

The country's efforts to create a Covid-19 vaccine will continue with the ground-breaking initiative on April 23.

The project at Imperial College London will receive £22.5 million to support its clinical trials and Oxford University will be granted £20 million.

Work on the vaccine, developed by clinical teams at the University of Oxford's Jenner Institute and Oxford Vaccine Group, began in January.

Now a study involving up to 510 healthy volunteers between 18 and 55 is to get under way in Oxford and Southampton, with three further sites likely to be added.

The UK will join only the US - with two studies - and China, in beginning human trials.